dence exists that higher dose has significantly more gastrointestinal complications. Therefore, if the doses are equally effective and high dose is used, some harm might result.
The designers of the first trials of aspirin in stroke prevention decided on a daily dose in the absence of any available guidelines. It was assumed that any beneficial effect would be related to the prevention of platelet aggregation by aspirin's inhibition of platelet thromboxane A 2 synthesis. In subsequent years, when it was established that as little as 40 mg a day could produce this effect, it was assumed by many that the original doses were too high. These studies in conjunction with the introduction of the homogenizing meta-analyses led some to believe that we can now recommend the appropriate dose of aspirin for stroke prevention. Others of us still consider the issue to be as yet unresolved.
In this issue of Stroke, Tohgi and his coworkers 3 report that the effect of low-to-high doses of aspirin on platelet aggregability necessary to prevent thrombogenesis varies in poststroke patients, depending on methods of evaluation. Different doses may be necessary to prevent thrombogenesis induced by different triggers of different strengths.
Aspirin After Transient Ischemic Attack and Minor Stroke
Our first concern is that none of the lower-dose studies in the original review of the Anti-platelet Trialists were of cerebrovascular disease. 4 These were primarily heart studies. None of the studies of cerebrovascular disease at that time demonstrated a statistically significant effectiveness of a dose of aspirin less than 975 mg/day. 5 -15 In the one direct comparison of 300 versus 1,200 mg/day, the United Kingdom Study, 1516 the numbers of patients in each aspirin group were far too small to rule out a type II error. Therefore, the recommendation that "if aspirin is to be used prophylactically in routine medical practice there appears to be no good reason to use a dose higher than 300-325 mg/day . . . " does not appear to be well founded.
Part of the bias for assuming that 325 mg aspirin or less a day is equivalent to or better than 975 mg or more is based on an assumption. Low doses, possibly as low as 30 mg/day, will block cyclooxygenase and the release of thromboxane A 2 in platelets and have very little or no effect on the prostacyclin system in the endothelium. Therefore, low dose might induce a desirable combination effect. This has not been established by a properly
